Cholinergic-dopaminergic imbalance in Pisa syndrome

Clinical Neuropharmacology

Volumn 26, Issue 3, 2003, Pages 119-121

  Villarejo, Alberto ^a   Camacho, Ana ^a   García Ramos, Rocío ^a   Moreno, Teresa ^a   Penas, Marta ^a   Juntas, Raúl ^a   Ruiz, Juan ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Dystonia; Parkinson's disease; Pisa syndrome; Risperidone Donepezil

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; NEUROLEPTIC AGENT; RISPERIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HUMAN; IDIOPATHIC DISEASE; NERVE DEGENERATION; PARKINSON DISEASE; PISA SYNDROME; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FEMALE; HUMANS; INDANS; PARKINSON DISEASE; PIPERIDINES; RISPERIDONE; SYNDROME; TREATMENT OUTCOME;

EID: 0038051877     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200305000-00004     Document Type: Article

References (20)

1. Ekbom K, Lindholm, Ljundberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972;202:94-103.
2. Suzuki T, Matsuzaka H. Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management. CNS Drugs 2002;16:165-74.
3. Kwak YT, Han IW, Baik J, et al. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222.
4. Miyaoka T, Seno H, Yamamori C, et al. Pisa syndrome due to cholinesterase inhibitor (donepezil): a case report. J Clin Psychiatry 2001;62:573-4.
5. Suzuki T, Koizumi J, Moroji T, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatry Scand 1990;82:454-7.
6. Yassa R, Nastase C, Cvejic J, et al. The Pisa syndrome (or pleurothotonus): prevalence in a psychogeriatric population. Biol Psychiatry 1991;29:942-5.
7. Steubner S, Padberg F, Grohmann R, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 2000;61:569-74.
8. Kurtz G, Kapfhammer HP, Peuker B. Pisa syndrome in clozapine therapy. Nervenarzt 1993;64:742-6.
9. Harada K, Sasaki N, Ikeda H, et al. Risperidone-induced Pisa syndrome. J Clin Psychiatry 2002;63:166.
10. Fichtner CG, Pechter BM, Jobe TH. Pisa syndrome mistaken for conversion in an adolescent. Br J Psychiatry 1992;161:849-52.
11. Padberg F, Stubner S, Buch K, et al. Pisa syndrome during treatment with sertindole. Br J Psychiatry 1998;173:351-2.
12. Suzuki T, Kurita H, Hori T, et al. The Pisa syndrome (pleurothotonus) during antidepressant therapy. BiolPsychiatry 1997;41:243-6.
13. Davidson M, Powchik P, Davis KL. Pisa syndrome in Alzheimer's disease. Biol Psychiatry 1988;23:213.
14. Patel S, Tariot PN, Hamill RW. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1991;4:48-51.
15. Tariot PN, Pendlebury W, Hamill R. Pisa syndrome without neuroleptic exposure in a patient with dementia of the Alzheimer type: a follow-up report. J Geriatr Psychiatry Neurol 1997;10:130.
16. Colosimo C. Pisa syndrome in a patient with multiple system atrophy. Mov Disord 1998;13:607-9.
17. Rosebuch PI, Mazurek MF. Neuroleptic side effects in neurologicnaive patients treated with haloperidol or risperidone. Neurology 1999;52:782-5.
18. Remington GJ. The Pisa syndrome: possible role for serotonin and noradrenaline. J Clin Psychopharmacol 1988;8:228-9.
19. Suzuki T, Hori T, Baba A, et al. Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). J Clin Psychopharmacol 1999;19:277-80.
20. Bhattacharya KF, Giannakikou I, Munroe N, et al. Primary anti-cholinergic-responsive Pisa syndrome. Mov Disord 2000;15: 1285-7.